Who holds exact sciences (exact) stock?
Only 1.40% of the stock of Exact Sciences is held by insiders. 88.78% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Earnings for Exact Sciences are expected to decrease in the coming year, from ($3.17) to ($3.30) per share.
How did exact sciences (EXAs) perform in Q4 earnings?
Exact Sciences Co. (NASDAQ:EXAS) released its quarterly earnings results on Monday, November, 1st. The medical research company reported ($0.97) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.89) by $0.08.
Where can I buy shares of EXAs?
Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is exact sciences's PE (price/earnings) ratio good or bad?
The P/E ratio of Exact Sciences is -15.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Exact Sciences is -15.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is EXAS a good buy?
Out of 8 analysts, 2 (25%) are recommending EXAS as a Strong Buy, 3 (37.5%) are recommending EXAS as a Buy, 3 (37.5%) are recommending EXAS as a Hold, 0 (0%) are recommending EXAS as a Sell, and 0 (0%) are recommending EXAS as a Strong Sell. What is EXAS's earnings growth forecast for 2022-2024?
Is EXAS overvalued?
Exact Sciences Corporation - Hold Valuation metrics show that Exact Sciences Corporation may be overvalued. Its Value Score of D indicates it would be a bad pick for value investors. The financial health and growth prospects of EXAS, demonstrate its potential to underperform the market.
Should I sell Exact Sciences stock?
12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Exact Sciences stock.
Who is the parent company of Cologuard?
Exact Sciences Corp. is a molecular diagnostics company specializing in the detection of early stage cancers. The company's initial focus was on the early detection and prevention of colorectal cancer, in 2014 it launched Cologuard, the first stool DNA test for colorectal cancer.
Will Exas go up?
The 16 analysts offering 12-month price forecasts for Exact Sciences Corp have a median target of 80.50, with a high estimate of 160.00 and a low estimate of 50.00. The median estimate represents a +77.35% increase from the last price of 45.39.
Is Exas profitable?
Past Earnings Growth Analysis Earnings Trend: EXAS is unprofitable, and losses have increased over the past 5 years at a rate of 42.9% per year. Earnings vs Industry: EXAS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Is Exact Sciences a good company to work for?
Is Exact Sciences a good company to work for? Exact Sciences has an overall rating of 3.7 out of 5, based on over 519 reviews left anonymously by employees. 72% of employees would recommend working at Exact Sciences to a friend and 58% have a positive outlook for the business.
When did Exas go public?
Exact Sciences is registered under the ticker NASDAQ:EXAS . Their stock opened with $14.00 in its Jan 31, 2001 IPO.
Does Pfizer own cologuard?
Pfizer quit on Cologuard a while ago In 2018, when Exact Sciences hired Pfizer to co-promote Cologuard, Pfizer was a very different company. Shortly after signing the agreement with Exact Sciences, Pfizer's former CEO Ian Read handed the leadership role to Albert Bourla.
What do gastroenterologists think of cologuard?
I feel most gastroenterologists would agree Cologuard is a potent weapon in the armamentarium against colon cancer. The 92 percent sensitivity for CRC, and 69 percent sensitivity for detection adenomas with high grade dysplasia, make it the standard second line option, next to colonoscopy.
Should I buy or sell Exact Sciences stock right now?
12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last twelve months. There are currently 3...
What is Exact Sciences' stock price forecast for 2022?
12 analysts have issued twelve-month price targets for Exact Sciences' stock. Their forecasts range from $50.00 to $155.00. On average, they antici...
How has Exact Sciences' stock performed in 2022?
Exact Sciences' stock was trading at $77.83 on January 1st, 2022. Since then, EXAS shares have decreased by 47.0% and is now trading at $41.23. Vi...
Are investors shorting Exact Sciences?
Exact Sciences saw a decline in short interest in the month of May. As of May 31st, there was short interest totaling 11,540,000 shares, a decline...
When is Exact Sciences' next earnings date?
Exact Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, July 27th 2022. View our earnings forecast for Exact...
How were Exact Sciences' earnings last quarter?
Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings results on Tuesday, April, 26th. The medical research company reported ($1.04) ea...
What guidance has Exact Sciences issued on next quarter's earnings?
Exact Sciences updated its FY 2022 earnings guidance on Tuesday, April, 26th. The company provided EPS guidance of for the period. The company issu...
Who are Exact Sciences' key executives?
Exact Sciences' management team includes the following people: Mr. Kevin T. Conroy , Chairman, Pres & CEO (Age 56, Pay $1.92M) ( LinkedIn Profil...
What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?
141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com . Kevin T. Conroy has an approval rating of 97% among Exact Sciences'...
What is Exact Sciences' stock price today?
What other stocks do shareholders of Exact Sciences own?
One share of EXAS stock can currently be purchased for approximately $74.13.
How can I listen to Exact Sciences' earnings call?
Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), salesforce.com (CRM), PayPal (PYPL), Square (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).
What are Wall Street analysts saying about Exact Sciences stock?
Interested parties can register for or listen to the call using this link or dial in at 647-362-9199 with passcode "4437608".
What is Kevin T. Conroy's approval rating as Exact Sciences' CEO?
The company exited the second quarter of 2021 with net loss wider than the Zacks Consensus Estimate. The widening of quarterly operating and net loss compared to the year-ago period is concerning. Revenues from the COVID-19 tests conducted during the quarter declined year over year. Further, Screening revenues registered a onetime downward adjustment of $12 million. The company also incurred significant operating loss on escalating costs and expenses. On a positive note, Exact Sciences reported better-than-expected revenues in the second quarter. Robust total revenue growth during the quarter, despite the pandemic-led headwinds, is impressive. The company’s legacy Screening business saw a significant improvement in revenues on Cologuard volume growth." (9/29/2021)
Where are Exact Sciences' headquarters?
141 employees have rated Exact Sciences CEO Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among Exact Sciences' employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.
What is the ticker symbol for exact sciences?
Exact Sciences is headquartered at 5505 ENDEAVOR LANE, MADISON WI, 53719.
What is the exact science?
Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."
What is market cap?
Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market ...
Does market cap include convertible securities?
Market Cap (Capitalization) is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements.
How many X is Zacks?
It does not include securities convertible into the common equity securities. "Market Cap" is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable).
How many sectors are there in Zacks?
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
What is the strongest cancer diagnostics brand?
The Zacks Sector Rank assigns a rating to each of the 16 Sectors based on their average Zacks Rank.
What is the exact science?
Following the consolidation, Exact Sciences currently has two of the strongest brands in cancer diagnostics, Cologuard and Oncotype DX.
What are the different grades for stocks?
Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and pre-cancer.
When did Exact Sciences acquire Genomic Health?
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
When did Genomic launch the DX test?
On Nov 8, 2019 , Exact Sciences completed the acquisition of Genomic Health for a value of approximately $2.8 billion. Prior to merger, Genomic Health was a prominent provider of genomic-based diagnostic tests in the field of cancer care. The company used to offer its line of products under the brand name Oncotype DX.
